N-甲基-N-苯基氨基甲酸甲酯 | 28685-60-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-甲基-N-苯基氨基甲酸甲酯
• 英文名称: N-carbomethoxy-N-methylaniline
• 英文别名: methyl N-methyl-N-phenylcarbamate；methyl N-methyl(phenyl)carbamate；N-methyl-N-phenylcarbamic acid methyl ester；Methylphenylamine, N-methoxycarbonyl-
• CAS: 28685-60-1
• 化学式: C₉H₁₁NO₂
• mdl: MFCD00457442
• 分子量: 165.192
• InChiKey: YFZJZJIUKMANKN-UHFFFAOYSA-N

物化性质

• 熔点：
  44°C
• 沸点：
  293.03°C (rough estimate)
• 密度：
  1.2960

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-甲基-N-苯基氨基甲酸甲酯 在 甲基锂 、 lithium bromide 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以95%的产率得到N-甲基苯胺
  参考文献：
  名称：

  Sawyer, J. Scott; Narayanan, Bikshandarkoil A., Synthetic Communications, 1983, vol. 13, # 2, p. 135 - 138

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(甲基(苯基)氨基)乙腈 在 copper(l) iodide 、 氧气 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 12.75h， 生成 N-甲基-N-苯基氨基甲酸甲酯
  参考文献：
  名称：

  2-(N-methylanilino)-2-phenylsulfanylacetonitrile, a reagent tested for electrophilic, nucleophilic and radical reactions

  摘要：

  2-(N-Methylanilino) -2-phenylsulfanylacetonitrile 1 has been readily prepared from 2-(N-methylanilino)acetonitrile and diphenyl disulfide. Alkylation of the anion of 1 with halogenoalkanes resulted in concurrent elimination of benzenethiol to give conjugated alpha-aminoalkenenitriles of 2E-configuration. Autoxidation of 1 in the presence of alkoxide ions afforded alkyl N-methyl-N-phenylcarbamates. Nucleophilic substitution of 1 with Grignard reagent or appropriate silyl compounds were promoted by Cul or Lewis acids to give varied alpha-amino nitriles. The 4-oxo-2-amino nitriles 9 obtained by condensation of 1 and titanium enolates can be considered as derivatives of 1,3-dicarbonyl compounds with the aldehyde group being activated to give an amino nitrile umpolung. When 1 was treated with tributylstannane, the corresponding amino nitrile alpha-radical was formed and the self-coupling product was isolated.

  DOI：

  10.1039/p19940002217

文献信息

• [EN] PROCESS FOR PREPARING ISOCYANATE COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ ISOCYANATE
  申请人：BASF SE

  公开号：WO2016177761A1

  公开（公告）日：2016-11-10

  The present invention relates to a process for the preparation of an isocyanate compound comprising the steps of: a) Reacting an amine compound A having at least one primary amino group with CO2 and an organotin compound S having at least one radical OR3 attached to the tin atom of the organotin compound, wherein R3 is a C-bound organic radical having from 1 to 30 carbon atoms, wherein 1, 2 or 3 carbon atoms may be replaced by oxygen or nitrogen, to convert at least one of the primary amino groups in the amine compound A into a carbamate group, thereby obtaining a carbamate compound C; b) cleavage of the carbamate groups in the carbamate compound C obtained in step a) to form the isocyanate compound and an alcohol R3OH, without separation of the tin compound formed in step a); c) obtaining the isocyanate compound from the reaction mixture of step b).

  本发明涉及一种用于制备异氰酸酯化合物的方法，包括以下步骤：a）使至少含有一个伯氨基的胺化合物A与CO2和至少含有一个连接到有机锡化合物锡原子的自由基OR3的有机锡化合物S反应，其中R3是一个具有1至30个碳原子的C-连接有机基团，其中1、2或3个碳原子可以被氧或氮替换，以将胺化合物A中的至少一个伯氨基转化为碳酸酯基团，从而获得碳酸酯化合物C；b）在步骤a）中获得的碳酸酯化合物C中的碳酸酯基团裂解，形成异氰酸酯化合物和醇R3OH，不分离步骤a）中形成的锡化合物；c）从步骤b）的反应混合物中获得异氰酸酯化合物。
• Aniline Carbamates: A Versatile and Removable Motif for Palladium-Catalyzed Directed CH Activation
  作者：Nick Uhlig、Chao-Jun Li

  DOI：10.1002/chem.201403712

  日期：2014.9.15

  ability as a directing group are demonstrated by its use in the ortho‐arylation of a wide variety of aniline derivatives under palladium(II) catalysis, with symmetric diaryliodonium salts as aryl donors. The reaction differs from previously reported arylations in its selectivity and its mechanism, as elucidated by kinetic and isotopic experiments. The directing group can also be easily removed under a

  苯胺氨基甲酸酯被引入作为对C新的可移动导向基团 ħ活化。它的多功能性和作为导向基团的能力通过在钯（II）催化下以对称的二芳基碘鎓盐作为芳基供体在各种苯胺衍生物的邻芳基化中使用而得到证明。如动力学和同位素实验所阐明的，该反应在选择性和机理上与先前报道的芳基化反应不同。导向基团也可以在多种条件下容易地除去。
• PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES
  申请人：Pfizer Inc.

  公开号：US20150329542A1

  公开（公告）日：2015-11-19

  A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A′ are independently C or N, where C may be unsubstituted or substituted by halo or C 1 -C 6 alkyl; R and R 0 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy(C 1 -C 6 alkyl), phenyl(C 1 -C 6 alkyl), and —(CH 2 ) n —W, where W is C 3 -C 8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N, S and/or O atoms, —SO 2 —R′, —NHSO 2 —R′, —NR″SO 2 —R′ and SR′, where R′ and R″ are independently C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R 0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, etc., or (b) —(CH 2 ) n —W, where W is C 3 -C 8 cycloalkyl, phenyl, etc.; R 1 is H, halo or cyano; R 2 and R 2′ are independently H, C 1 -C 6 alkyl, cyano, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, or C 3 -C 8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, —CO—, —CONH—, —SO 2 —, —SONH—, or —(CH 2 ) m —; R 3 is H, C 1 -C 4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent —Y—R 4 and/or 1-4 substituents each independently selected from R 5 ; with the proviso that when X is —CO— or —SO 2 —, R 3 is not H; Y is a bond, —(CH 2 ) m — or —O—; R 4 is (a) H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, halo, oxo, —OR 6 , —NR 7 R 8 , —SR 6 , —SOR 9 , —SO 2 R 9 , —COR 6 , —OCOR 6 , —OCOR 6 , —NR 6 COR 6 , —CONR 7 R 8 , etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, halo, cyano, —OR 6 , —NR 7 R 8 , etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R 6 is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, etc.; R 7 and R 8 are each independently H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C 1 -C 6 alkyl is optionally substituted by C 3 -C 8 cycloalkyl, halo, etc., and said heterocyclic ring being optionally substituted by one or more C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl groups; R 9 is C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

  具有以下结构的化合物： 或其药学上可接受的盐，或所述化合物或药学上可接受的盐的药学上可接受的溶剂，其中A和A′独立地为C或N，其中C可以是未取代的或由卤素或C 1 -C 6 烷基取代的；R和R 0 独立地选自H、C 1 -C 6 烷基、羟基(C 1 -C 6 烷基)、苯基(C 1 -C 6 烷基)和—(CH 2 ) n —W的群，其中W为C 3 -C 8 环烷基、苯基、萘基、含有1-3个N、S和/或O原子的5-或6元杂环芳基或杂环烷基，—SO 2 —R′、—NHSO 2 —R′、—NR″SO 2 —R′和SR′，其中R′和R″独立地为C 1 -C 6 烷基或C 3 -C 8 环烷基等；其中所述的每个烷基、环烷基、杂环、苯基、萘基或杂芳基可以是未取代的或由苯基、杂芳基等取代的；或者，R和R 0 以及它们结合的N原子共同形成一个可以是未取代的或由(a)卤素、羟基、杂芳基、C 1 -C 6 烷基、C 1 -C 6 烷氧基等取代的单环或双环杂环环，或(b) —(CH 2 ) n —W，其中W为C 3 -C 8 环烷基、苯基等；R 1 为H、卤素或氰基；R 2 和R 2′ 独立地为H、C 1 -C 6 烷基、氰基、C 1 -C 6 烷氧基、C 1 -C 6 烷硫基或C 3 -C 8 环烷基，其中烷基、烷氧基或环烷基可以选择性地由一个或多个氟原子取代；X为键，—CO—、—CONH—、—SO 2 —、—SONH—或—(CH 2) m —；R 3 为H、C 1 -C 4 烷基、苯基、萘基、含有1-3个N原子的5-或6元杂环芳基或杂环，一种5元杂环芳基或杂环等，或(c) 2个O或S原子和0-2个N原子；其中所述的每个苯基、萘基、杂芳基或杂环可以选择性地由烷基、1个取代基—Y—R 4 和/或1-4个独立选择自R 5 的取代基取代；但是当X为—CO—或—SO 2 —时，R 3 不是H；Y为键，—(CH 2) m —或—O—；R 4 为(a) H、C 1 -C 6 烷基、C 3 -C 8 环烷基、卤素、氧代、—OR 6 、—NR 7 R 8 、—SR 6 、—SOR 9 、—SO 2 R 9 、—COR 6 、—OCOR 6 、—OCOR 6 、—NR 6 COR 6 、—CONR 7 R 8 等；(b)苯基或萘基，所述的苯基和萘基可以选择性地由1-5个取代基选自C 1 -C 6 烷基、C 3 -C 8 环烷基、卤素、氰基、—OR 6 、—NR 7 R 8 等取代；或(c) 3到8元饱和或部分不饱和的单环杂芳基等；R 6 为H、C 1 -C 6 烷基或C 3 -C 8 环烷基等；R 7 和R 8 独立地为H、C 1 -C 6 烷基或C 3 -C 8 环烷基，或者与它们连接的氮原子共同形成含有1-2个氮原子或1个氮原子和1个氧原子的4、5或6元饱和杂环环，所述的C 1 -C 6 烷基可以选择性地由C 3 -C 8 环烷基、卤素等取代，所述的杂环环可以选择性地由一个或多个C 1 -C 6 烷基或C 3 -C 8 环烷基基团取代；R 9 为C 1 -C 6 烷基或C 3 -C 8 环烷基；m和n独立地为0、1、2或3。该发明还涉及这些化合物的药学上可接受的盐和其药学上可接受的溶剂；含有这种化合物的组合物；以及这种化合物在治疗各种疾病，特别是哮喘和慢性阻塞性肺病中的用途。
• Copper-Catalyzed Coupling of Amines with Carbazates: An Approach to Carbamates
  作者：Song-Ning Wang、Guo-Yu Zhang、Adedamola Shoberu、Jian-Ping Zou

  DOI：10.1021/acs.joc.1c01031

  日期：2021.7.2

  A new approach for the preparation of carbamates via the copper-catalyzed cross-coupling reaction of amines with alkoxycarbonyl radicals generated from carbazates is described. This environmentally friendly protocol takes place under mild conditions and is compatible with a wide range of amines, including aromatic/aliphatic and primary/secondary substrates.

  描述了一种通过胺与由氨基甲酸酯产生的烷氧基羰基的铜催化交叉偶联反应制备氨基甲酸酯的新方法。这种环境友好的协议在温和的条件下进行，并且与多种胺兼容，包括芳香族/脂肪族和初级/次级底物。
• Dimethyl Carbonate as an Ambident Electrophile
  作者：Pietro Tundo、Laura Rossi、Alessandro Loris

  DOI：10.1021/jo048532b

  日期：2005.3.1

  character (aliphatic and aromatic amines, alcohoxydes, phenoxides, thiolates) are compared with regard to nucleophilic substitutions on dimethyl carbonate (DMC), using different reaction conditions. Results are well in agreement with the Hard−Soft Acid−Base (HSAB) theory. Accordingly, the high selectivity of monomethylation of CH2 acidic compounds and primary aromatic amines with DMC can be explained

  使用不同的反应条件，对碳酸二甲酯（DMC）上的亲核取代进行了比较，对具有不同软/硬特性的各种阴离子（脂肪族和芳香族胺，烷氧基，酚盐，硫醇盐）的特征进行了比较。结果与硬质酸碱（HSAB）理论完全吻合。因此，CH 2的单甲基化的高选择性DMC中的酸性化合物和伯芳族胺可以通过两个不同的后续反应来解释，这是由于DMC具有双重亲电特性。第一步由硬-硬反应组成，选择性地产生软阴离子，在第二相中，通过软-软亲核取代（使用DMC，在完全转化时收率> 99％）选择性转化为最终的单甲基化产物作为溶剂）。